GlassScriptPhysician profile
Erika Lancaster
NPI 1053900936
$1,506.59
in general payments reported to CMS, 2019-2025
21 companies · $604 in 2025
The $604 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $90.26 · 2024: $813 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $361.85 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Indivior INC. | $180.91 | 2024-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $179.74 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $94.36 | 2024 | |
| Gilead Sciences, INC. | $83.32 | 2024-2025 | |
| Amgen INC. | $72.44 | 2023-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $68.24 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $61.43 | 2024-2025 | Uzedy, Austedo Xr |
| Corcept Therapeutics | $58.69 | 2025 | Korlym |
| Pfizer INC. | $53.80 | 2024-2025 | |
| Braeburn INC. | $51.33 | 2024-2025 | Brixadi |
| Merck Sharp & Dohme LLC | $40.61 | 2023-2025 | Verquvo, Belsomra |
| Lilly USA, LLC | $36.82 | 2025 | Mounjaro |
| Beta Bionics, INC. | $22.94 | 2024 | Ilet Bionic Pancreas |
| Axsome Therapeutics, INC. | $22.90 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $22.60 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $22.23 | 2025 | |
| Ardelyx, INC. | $19.64 | 2023 | Ibsrela |
| Vanda Pharmaceuticals INC. | $19.41 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.60 | 2023 | |
| Uswm, LLC | $15.73 | 2024 | Lucemyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.